Nos EUA, a incidência de policitemia vera (PV) é relatada como sendo de 1.57 por 100,000 pessoas-ano (dados de 2002 a 2016).[11]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
Na Europa, a incidência anual é de 0.4 a 2.8 por 100,000 pessoas.[20]Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014 Apr;92(4):289-97.
http://www.ncbi.nlm.nih.gov/pubmed/24372927?tool=bestpractice.com
No Reino Unido, a incidência anual de PV é de 1.8 por 100,000, com uma estimativa de 1140 pessoas recém-diagnosticadas a cada ano (dados de 2010 a 2019).[21]Haematological Malignancy Research Network (HMRN). Cancer factsheets: polycythaemia vera. May 2024 [internet publication].
https://hmrn.org/factsheets#polycythaemia_vera
A PV ocorre mais comumente em homens (a razão entre homens/mulheres é de aproximadamente 1.6 nos EUA e 1.2 no Reino Unido).[11]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[21]Haematological Malignancy Research Network (HMRN). Cancer factsheets: polycythaemia vera. May 2024 [internet publication].
https://hmrn.org/factsheets#polycythaemia_vera
A incidência nos EUA é relatada como sendo mais alta entre os brancos.[11]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
O aumento da incidência e da prevalência de PV foi relatado nas comunidades judaicas Ashkenazi.[22]Modan B, Kallner H, Zemer D, et al. A note on the increased risk of polycythemia vera in Jews. Blood. 1971 Feb;37(2):172-6.
http://bloodjournal.hematologylibrary.org/cgi/reprint/37/2/172
http://www.ncbi.nlm.nih.gov/pubmed/5549194?tool=bestpractice.com
[23]Chaiter Y, Brenner B, Aghai E, et al. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma. 1992 Jun;7(3):251-5.
http://www.ncbi.nlm.nih.gov/pubmed/1477653?tool=bestpractice.com
[24]Le M, Ghazawi FM, Rahme E, et al. Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada. Cancer. 2019 Nov 15;125(22):3953-9.
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32417
http://www.ncbi.nlm.nih.gov/pubmed/31381139?tool=bestpractice.com
A PV afeta mais comumente pessoas de meia-idade e idosas (aproximadamente 63% dos pacientes nos EUA têm idade ≥60 anos no momento do diagnóstico), mas pode ocorrer em qualquer idade.[11]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
A idade mediana no momento do diagnóstico é de 65 anos nos EUA e 71 anos no Reino Unido.[11]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[21]Haematological Malignancy Research Network (HMRN). Cancer factsheets: polycythaemia vera. May 2024 [internet publication].
https://hmrn.org/factsheets#polycythaemia_vera
A prevalência de PV foi relatada entre 22 e 57 por 100,000 nos EUA.[9]Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Apr;32(3):171-3.
http://www.ncbi.nlm.nih.gov/pubmed/16673273?tool=bestpractice.com
[25]Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008 May;83(5):359-62.
http://www.ncbi.nlm.nih.gov/pubmed/18181200?tool=bestpractice.com
[26]Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014 Jun;89(6):581-7.
https://onlinelibrary.wiley.com/doi/10.1002/ajh.23690
http://www.ncbi.nlm.nih.gov/pubmed/24971434?tool=bestpractice.com
[27]Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600.
http://www.ncbi.nlm.nih.gov/pubmed/23768070?tool=bestpractice.com
Dados globais, fora dos EUA e da Europa Ocidental, são escassos.
A PV é extremamente rara em crianças.[10]Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009 Aug;88(8):713-9.
http://www.ncbi.nlm.nih.gov/pubmed/19468728?tool=bestpractice.com
[28]Ishida H, Miyajima Y, Hyakuna N, et al. Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: a retrospective nationwide survey. EJHaem. 2020 Jul;1(1):86-93.
https://onlinelibrary.wiley.com/doi/10.1002/jha2.39
http://www.ncbi.nlm.nih.gov/pubmed/35847744?tool=bestpractice.com